Dr Michael Baker interviewed by JustStocks

MediaAll
Written By Michelle Long

Arovella Therapeutics Ltd (ASX:ALA) CEO Dr Michael Baker caught up with JustStocks Video following news the company has appointed three key opinion leaders and clinical oncologists to establish its Clinical Advisory Board (CAB).

The CAB will provide expert clinical insight and strategic advice focusing on CD19-positive haematological malignancies (blood cancers), as the Company looks to file its IND and commence its first-in-human phase 1 clinical trial.

View the ASX release announcing Arovella’s Clinical Advisory Board.

 
Michelle Long
Previous

Arovella receives R&D tax rebate of $3.0 million with a further $0.3 million expected
Next

Investor Presentation